ESMO
Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024
Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile
Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5
Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto
Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
Exact Sciences Advances Toward FDA Submission with Promising Blood-Based Colorectal Cancer Screening Test
Exact Sciences, Blood-Based Colorectal Cancer Screening, ESMO 2024, FDA Submission, Colorectal Cancer Detection, Advanced Precancerous Lesions
ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns
Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial